Clinical trials: Colorectal Liver Metastasis (CRLM)
Liver Neoplasms, Hepatobiliary Diseases
Outcomes After Liver and Biliary Resection at a High-Volume Center
The goal of this observational study is to evaluate clinical and oncologic outcomes in adult patients undergoing liver and/or biliary resection for benign and malignant diseases.
- Conditions
- Liver Neoplasms, Hepatobiliary Diseases, Cholangiocarcinoma, Hepatocellular Carcinoma
- Trial name
- BILIVER (NCT07556835)
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Azienda USL Toscana Centro
Colorectal Liver Metastases
Laparoscopic Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) for Colorectal Liver Metastases (CRLM)
Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a procedure used for patients with initially unresectable colorectal liver metastases (CRLM).
- Trial name
- NCT06779474
- Testing
- Laparoscopic ALPPS
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Yanhong Deng
Hepatocellular Carcinoma, Hepatocellular Cancer
Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
This is a single arm phase II study of adjuvant intra-dermal NA DC vaccine combined with intravenous nivolumab in patients with resectable HCC (group A) or CRLM (group B) planned for curative surgery (with/without local ablation).
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Colorectal Cancer, Colorectal Carcinoma
- Trial name
- NCT04912765
- Testing
- Neoantigen Dendritic Cell Vaccine, Nivolumab
- Where
- Singapore
- Volunteers
- 60 people
- Sponsor
- National Cancer Centre, Singapore
Colorectal Liver Metastases
High- and Low-dose Radiotherapy Combined With PD-1 Inhibitors for MSS CRLM
This pilot phase I trial aims to investigate the efficacy and safety of high- and low-dose radiotherapy combined with programmed cell death-1 (PD-1) inhibitors in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)…
- Trial name
- HaRyPOT (NCT06045286)
- Testing
- Radiation: High- and Low-dose radiotherapy, PD-1 Inhibitors
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Colorectal Cancer Liver Metastases (CRLM)
AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC)
This is a prospective, randomized controlled, single-center phase II clinical study. It aims to compare the efficacy of AK104 plus radiotherapy combined with standard therapy versus standard therapy as first-line treatment for…
- Trial name
- APSOC (NCT07544784)
- Testing
- AK104 with radiotherapy, Standard of therapy
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Fudan University
Long-term Oncologic Outcome of MILS in Patients With CRLM and Prognostic Indicators
Minimally Invasive Liver Surgery for Metastases From Colorectal Cancer: Oncologic Outcome and Prognostic Factors
Only few reports exist on long-term survival after minimally invasive liver surgery (MILS for colorectal liver metastases. No data are available assessing prognostic factors in the era of current modern treatment strategies.
- Trial name
- NCT01356706
- Where
- Belgium
- Volunteers
- 274 people
- Sponsor
- University Hospital, Gasthuisberg
Colorectal Cancer Liver Metastasis
Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM
To date no prospective trials have been completed that demonstrated whether RFA is an effective adjunct to systemic chemotherapy (target therapy) with respect to advantages in overall survival compared with chemotherapy (target…
- Trial name
- NCT03127072
- Testing
- Radiofrequency Ablation (RFA), chemotherapy ± target therapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University
Colorectal Liver Metastasis (CRLM)
Multi-Reader Multi-Case Trial Evaluating Computer-Aided Tool for Prognostic Prediction of Colorectal Liver Metastases
This study evaluates the impact of a novel computer-aided prognostic prediction tool for colorectal liver metastases (CRLM) on clinician performance.
- Trial name
- NCT07027605
- Where
- China
- Volunteers
- 166 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences